ReviewMolecular cancer2026
Advanced 3D cancer models for analyzing tumor-immune cell interaction and therapeutic response.
Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A pancreatic cancer organoid-macrophage co-culture using starPEG-heparin hydrogel deciphers tumor-immune cell interactions.NPJ precision oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Immunotherapy is transforming the treatment of cancer by activating and directing a patient's own immune response to target tumor cells. In solid tumors, however, there has been limited success in sustaining anti-tumor immune responses. This is attributed to the intrinsic features of the tumor microenvironment, including the lack of infiltrating immune cells and varying expression of tumor antigens, forming an immunosuppressive landscape. Despite recent advances, we do not fully understand how the immune components of the tumor microenvironment are linked to ineffective treatment outcomes. Advanced 3D cancer models offer a platform to deconstruct tumor tissues and study disease progression and resistance to treatment, helping to uncover drivers of immune evasion in a physiologically relevant context. Here, we discuss aspects of the tumor immune microenvironment in selected solid tumors defined by distinct immunosuppressive features that dictate response to immunotherapy. We highlight how advanced 3D cancer models accelerate the development and screening of therapeutic strategies that target the immunosuppressive microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.